Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on hematologic disorders and cancer, marketing TAVALISSE (fostamatinib) for chronic immune thrombocytopenia, REZLIDHIA (olutasidenib) for relapsed or refractory AML with an IDH1 mutation, and GAVRETO (pralsetinib) for RET fusion-positive cancers.
Rigel Pharmaceuticals highlighted new GAVRETO (pralsetinib) data across RET fusion-positive cancers in oral and poster presentations at ESMO Congress 2026.
Leadership Team
Raul Rodriguez
President and Chief Executive Officer
Dean Schorno
Executive Vice President and Chief Financial Officer